Among the world's top biopharmaceutical companies

All of the elements required for outsourcing biopharmaceutical development and manufacture, from high expression system to fill & finish, and patient convenient application systems can be found within the corporate capabilities of Boehringer Ingelheim in a so called One-Stop-Shop.

At our large-scale production sites in Vienna, Austria and Biberach, Germany we have extablished a strong track record in regulatory approval since more than 25 years. So far 19 DNA-derived biopharmaceutical products have been successfully introduced to the market.

A well-filled R&D pipeline

One of our major efforts is the development of new biological entities (NBEs) for the treatment of diseases in the areas of:

• Respiratory
• Cardiovascular
• Virology
• Neurology (CNS)
• Immunology
  
• Metabolism
• Oncology

All R&D activities in these therapeutic areas are supported by Licensing for early and late stage pharmaceutical and biopharmaceutical products.